Intra-Cellular Therapies (NASDAQ:ITCI) has been the subject of diverse analyst ratings over the last three months, with a total of 18 analysts offering opinions ranging from bullish to bearish. The average 12-month price target for ITCI has been raised to $91.94, marking an 11.44% increase from the previous average of $82.50. Analysts from firms including Needham, Cantor Fitzgerald, Canaccord Genuity, Mizuho, Goldman Sachs, B of A Securities, TD Cowen, Baird, and RBC Capital have updated their ratings and price targets, reflecting a generally positive outlook on the company's performance. Intra-Cellular Therapies, a biopharmaceutical company focusing on central nervous system diseases, has shown a notable revenue growth rate of 50.41% over the past three months, despite challenges in net margin, ROE, and ROA.